<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/5BFB9036-9D16-4AB9-A9EF-097BB6FBD69A"><gtr:id>5BFB9036-9D16-4AB9-A9EF-097BB6FBD69A</gtr:id><gtr:name>Aston University</gtr:name><gtr:department>Sch of Life and Health Sciences</gtr:department><gtr:address><gtr:line1>Aston Triangle</gtr:line1><gtr:line4>Birmingham</gtr:line4><gtr:postCode>B4 7ET</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5BFB9036-9D16-4AB9-A9EF-097BB6FBD69A"><gtr:id>5BFB9036-9D16-4AB9-A9EF-097BB6FBD69A</gtr:id><gtr:name>Aston University</gtr:name><gtr:address><gtr:line1>Aston Triangle</gtr:line1><gtr:line4>Birmingham</gtr:line4><gtr:postCode>B4 7ET</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/C32E9430-021D-4676-85DE-838CD7B384A0"><gtr:id>C32E9430-021D-4676-85DE-838CD7B384A0</gtr:id><gtr:firstName>Asif</gtr:firstName><gtr:surname>Ahmed</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0700288"><gtr:id>B7093D04-36C2-40C5-9D6D-6C232C068D33</gtr:id><gtr:title>The Role of Endogenous Vascular Protection Factors in Preeclampsia</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0700288</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>Preeclampsia (PE) is a systemic endothelial disease defined clinically as hypertension and proteinuria after 20 weeks gestation. PE involves oxidative stress, dysregulation of placental angiogenesis including the release of soluble anti-angiogenic factors that induce systemic endothelial dysfunction. Little attention has been focussed on endogenous vascular protective factors that may inhibit anti-angiogenic factors such as soluble Flt-1 (sFlt-1; a VEGF antagonist) and soluble endoglin (sEng) that are elevated in preeclampsia. This programme will address the central hypothesis that preeclampsia is the result of a perturbation(s) in the vascular protective factors such as the important cytoprotective and anti-inflammatory enzyme, heme oxygenase-1 (HO-1), Thioredoxin reductase-1 (TrxR) and glutathione peroxidase-1 (Gpx), which function to tightly regulate pro- (Vascular endothelial growth factor-A (VEGF) / endothelial nitric oxide (NO) synthase (eNOS) and anti-angiogenic (sFlt-1 / sEng) factors possibly under the control of the phosphoinositide 3-kinase (PI 3-kinase) / Akt pathway. We propose that the HO/TrxR/GpX via PI 3-kinase /Akt pathways are defective in preeclampsia resulting in increased oxidative stress and exacerbated inflammation leading to the aberrant expression of anti-angiogenic factors (sFlt-1 / sEng) in the placenta. This hypothesis will be examined using three experimental systems (i) primary trophoblast and endothelial cell cultures, (ii) a human placental villous explant model and (iii) two transgenic mouse models of preeclampsia. The mechanism by which HO-1 modulates sFlt-1 and sEng expression mediated by pro-inflammatory cytokines (TNF-alpha, IL-1beta, IFN-gamma) and growth factors (VEGF, Ang-II) will be determined by manipulating the PI 3-kinase/PDK-1/Akt, phospholipase C-gamma1 and protein kinase C signal transduction pathways in these systems. This will be achieved by selective RNAi-mediated gene knockdown or over-expression of wild-type and dominant-negative / constitutively active mutants of the appropriate signalling proteins using adenoviral vectors. Understanding the mechanisms that reduce the prevalence of oxidative stress, inflammatory and anti-angiogenic mediators in preeclampsia may prolong pregnancy, prevent premature delivery, and protect the mother post-partum from persistent endothelial cell activation, which increases her predisposition to cardiovascular disease.</gtr:technicalSummary><gtr:fund><gtr:end>2014-02-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-06-09</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>2713469</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>College of Medical and Dental Sciences</gtr:department><gtr:description>Stuart Egginton</gtr:description><gtr:id>E645EC29-585B-48B3-8C29-F4617D3D206C</gtr:id><gtr:impact>Its too early to have output that is quantifiable.</gtr:impact><gtr:outcomeId>RNSLNEnYMe7-1</gtr:outcomeId><gtr:partnerContribution>Dr Stuart Egginton has helped my group learn about in vivo physiological measurements in mice.</gtr:partnerContribution><gtr:piContribution>I have provided the manpower and transgenic animals, which has initiated a study to help Dr Egginton develop new line of research using molecular approach. We will get several publications together and hope to apply for a MRC partnership grant.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>6th International Conference Heme Oxygenase, Miami, Florida</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>70F1EE35-7F5D-4E18-A18E-F630E2D64015</gtr:id><gtr:impact>6th International Conference Heme Oxygenase, Miami, Florida

Invited to write a review for leading Journal.</gtr:impact><gtr:outcomeId>A6BFBBA16C7</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ISSHIP 15th World Congress, Washington</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7D072CD3-D93B-467F-A2AE-BE10A68198A2</gtr:id><gtr:impact>15th World Congress held in Washington by International Society for Hypertension in Pregnancy.

Awareness of our work</gtr:impact><gtr:outcomeId>22B3FBCD6DC</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Biochemical Society - Molecular and Cellular Mechanisms</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4FC745E5-B415-4270-8772-6276C0EA0BB6</gtr:id><gtr:impact>Symposium on Angiogenesis

Invited to write a review and offers of collaboration.</gtr:impact><gtr:outcomeId>DA185A821BA</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>India-UK Scientific Seminars</gtr:description><gtr:end>2014-03-02</gtr:end><gtr:fundingOrg>The Royal Society</gtr:fundingOrg><gtr:id>34380818-F992-4E5C-9B1C-51CEC9B8E920</gtr:id><gtr:outcomeId>eKZLD3RcegD</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BHF Research Grant</gtr:description><gtr:end>2013-02-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>8FB7996F-6578-4C7E-A992-2C7CE2BEFB88</gtr:id><gtr:outcomeId>D7510559FE70</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>Statins for use in Preeclampsia</gtr:description><gtr:id>A757F5F8-9917-4178-AC5C-DC6A24CBC7DD</gtr:id><gtr:impact>World's first RCT underway. - StAmP.</gtr:impact><gtr:outcomeId>Ta5c91yuQZh</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>StAmP</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2008</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have identified potentially a new biomarker using our mouse model, which we are planing to test in our human population samples.</gtr:description><gtr:id>2007CA76-E247-4337-A6B8-ECA9ED30A181</gtr:id><gtr:impact>Too early to talk about it as its too preliminary.</gtr:impact><gtr:outcomeId>rTWxPwbRw7J</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>PreDict</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Generated a synthetic ligand that binds specifically to heterodimers of VEGF receptor-1 (VEGFR-1) and VEGFR-2 we have called VEGFR1-2. The dimeric ligand comprises one VEGFR-2-specific monomer (VEGF-E) and a VEGFR-1-specific monomer (PlGF-1) used to study endothelial cell homeostasis.</gtr:description><gtr:id>8E46D4AB-1CC3-4E85-84AF-BADDE7FCF584</gtr:id><gtr:impact>Other research group recieved MRC funding to work further on this project.</gtr:impact><gtr:outcomeId>ePFuCbpJTbr</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>VEGFR1:VEGFR2 selective ligand</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>generated virus for overexpression of key enzymes under investigation</gtr:description><gtr:id>2E11A75A-4B1B-4836-BA70-F470BDE2137B</gtr:id><gtr:impact>Publication in Circulation and led to patent application.</gtr:impact><gtr:outcomeId>QDWQXu1T7Q7</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>adenovirus for specific enzymes under investigation</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>792FC370-7BA3-461F-93FA-63CD50987AEC</gtr:id><gtr:title>Carbon monoxide inhibits sprouting angiogenesis and vascular endothelial growth factor receptor-2 phosphorylation.</gtr:title><gtr:parentPublicationTitle>Thrombosis and haemostasis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/378c2178deeae7c8e4ad76a33c2416f8"><gtr:id>378c2178deeae7c8e4ad76a33c2416f8</gtr:id><gtr:otherNames>Ahmad S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0340-6245</gtr:issn><gtr:outcomeId>545e615beafb06.13828485</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D5A5B78D-A394-4178-AA07-1207DD56D0BC</gtr:id><gtr:title>Angiopoietin-2 confers Atheroprotection in apoE-/- mice by inhibiting LDL oxidation via nitric oxide.</gtr:title><gtr:parentPublicationTitle>Circulation research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b268a5b4f18e012b49c9c4df08170ee"><gtr:id>5b268a5b4f18e012b49c9c4df08170ee</gtr:id><gtr:otherNames>Ahmed A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0009-7330</gtr:issn><gtr:outcomeId>AB14AC2A41C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F01A7C2C-8253-4644-986E-D811566EF010</gtr:id><gtr:title>Response to letter regarding article, &amp;quot;dysregulation of hydrogen sulfide (H2S) producing enzyme cystathionine ?-lyase (CSE) contributes to maternal hypertension and placental abnormalities in preeclampsia&amp;quot;.</gtr:title><gtr:parentPublicationTitle>Circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5f5948b5a7f162e349b3184da5420ba0"><gtr:id>5f5948b5a7f162e349b3184da5420ba0</gtr:id><gtr:otherNames>Wang K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0009-7322</gtr:issn><gtr:outcomeId>54074723b3d807.29434459</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8320BDA1-5DAA-411E-B166-83F26C6EA3E8</gtr:id><gtr:title>Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f79d195d7bc0e84a40af15e0b108a5d2"><gtr:id>f79d195d7bc0e84a40af15e0b108a5d2</gtr:id><gtr:otherNames>Kanasaki K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>ADE983163F3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C9979AE9-5FB5-4BDA-98BA-01549267789F</gtr:id><gtr:title>Angiopoietin-1 induces migration of monocytes in a tie-2 and integrin-independent manner.</gtr:title><gtr:parentPublicationTitle>Hypertension (Dallas, Tex. : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/378c2178deeae7c8e4ad76a33c2416f8"><gtr:id>378c2178deeae7c8e4ad76a33c2416f8</gtr:id><gtr:otherNames>Ahmad S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0194-911X</gtr:issn><gtr:outcomeId>NQf5nBw43RQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56162F22-D81B-4379-BC71-51425E1F15A0</gtr:id><gtr:title>Placenta growth factor-1 exerts time-dependent stabilization of adherens junctions following VEGF-induced vascular permeability.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ad2b1e9bc82f6c5c24c365dd4a584a4f"><gtr:id>ad2b1e9bc82f6c5c24c365dd4a584a4f</gtr:id><gtr:otherNames>Cai J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>doi_55f98498457e7610</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B42E1F80-EDB2-4A7B-AD29-143105965382</gtr:id><gtr:title>Activation of proteinase-activated receptor 2 stimulates soluble vascular endothelial growth factor receptor 1 release via epidermal growth factor receptor transactivation in endothelial cells.</gtr:title><gtr:parentPublicationTitle>Hypertension (Dallas, Tex. : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/62f873f073f3e3dc32f6d6711448ce11"><gtr:id>62f873f073f3e3dc32f6d6711448ce11</gtr:id><gtr:otherNames>Al-Ani B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0194-911X</gtr:issn><gtr:outcomeId>pm_13962_22_20124108</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22792FE5-6BFA-404A-B54F-DB314F4C04FB</gtr:id><gtr:title>Hydrogen sulfide: A novel mechanism for the vascular protection by resveratrol under oxidative stress in mouse aorta.</gtr:title><gtr:parentPublicationTitle>Vascular pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/69a6bca35ad610ad29aee060a4f72b91"><gtr:id>69a6bca35ad610ad29aee060a4f72b91</gtr:id><gtr:otherNames>Yetik-Anacak G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1537-1891</gtr:issn><gtr:outcomeId>58991ac9912ca2.37750261</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>72C43022-21EB-47A1-A58E-B08A304F6262</gtr:id><gtr:title>Flt1 acts as a negative regulator of tip cell formation and branching morphogenesis in the zebrafish embryo.</gtr:title><gtr:parentPublicationTitle>Development (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be5026317591425446a36c3053435cbc"><gtr:id>be5026317591425446a36c3053435cbc</gtr:id><gtr:otherNames>Krueger J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0950-1991</gtr:issn><gtr:outcomeId>th61K9tLifh</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AD94DFCD-A9CF-4AC6-B400-566A0A1C33EE</gtr:id><gtr:title>Heterodimerisation between VEGFR-1 and VEGFR-2 and not the homodimers of VEGFR-1 inhibit VEGFR-2 activity.</gtr:title><gtr:parentPublicationTitle>Vascular pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e992aab3e8840fffd19564dde9896985"><gtr:id>e992aab3e8840fffd19564dde9896985</gtr:id><gtr:otherNames>Cai M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1537-1891</gtr:issn><gtr:outcomeId>58991a795673b7.26042189</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>719EF433-4910-4933-9842-6369A11558D1</gtr:id><gtr:title>Fetal growth restriction results in remodeled and less efficient hearts in children.</gtr:title><gtr:parentPublicationTitle>Circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db04f47e38562b5929cb4cb7fd0366fe"><gtr:id>db04f47e38562b5929cb4cb7fd0366fe</gtr:id><gtr:otherNames>Crispi F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0009-7322</gtr:issn><gtr:outcomeId>pm_13962_22_20497977</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>39A04034-F677-42B0-B807-D1974DA8E420</gtr:id><gtr:title>The role of H2S bioavailability in endothelial dysfunction.</gtr:title><gtr:parentPublicationTitle>Trends in pharmacological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/17f6633e9d8a0b4804343fbc2df4165c"><gtr:id>17f6633e9d8a0b4804343fbc2df4165c</gtr:id><gtr:otherNames>Wang R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0165-6147</gtr:issn><gtr:outcomeId>5675e6613ba97</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>132A899E-C1C3-43D5-B5DB-3A83D34EFFB4</gtr:id><gtr:title>Carbon monoxide expedites metabolic exhaustion to inhibit tumor growth.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba033bc7077768019119d506b1113191"><gtr:id>ba033bc7077768019119d506b1113191</gtr:id><gtr:otherNames>Wegiel B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>pm_13962_22_24121491</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51DFEBF0-FF0C-4BD9-8890-54314C567666</gtr:id><gtr:title>Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling.</gtr:title><gtr:parentPublicationTitle>Hypertension (Dallas, Tex. : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25df2dcee136244bf1dc96c1beb9c9e5"><gtr:id>25df2dcee136244bf1dc96c1beb9c9e5</gtr:id><gtr:otherNames>Zhou CC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0194-911X</gtr:issn><gtr:outcomeId>14DF50DB7CD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D0324DCB-E391-439B-8D35-04FFA5B0D45D</gtr:id><gtr:title>Resveratrol inhibits the release of soluble fms-like tyrosine kinase (sFlt-1) from human placenta.</gtr:title><gtr:parentPublicationTitle>American journal of obstetrics and gynecology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3df86efa291578c18d072c2f5017785c"><gtr:id>3df86efa291578c18d072c2f5017785c</gtr:id><gtr:otherNames>Cudmore MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0002-9378</gtr:issn><gtr:outcomeId>pm_13962_22_22197494</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>04B7F530-D256-4C8B-BBEC-E8A3EA2FB459</gtr:id><gtr:title>Cardiac dysfunction and cell damage across clinical stages of severity in growth-restricted fetuses.</gtr:title><gtr:parentPublicationTitle>American journal of obstetrics and gynecology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db04f47e38562b5929cb4cb7fd0366fe"><gtr:id>db04f47e38562b5929cb4cb7fd0366fe</gtr:id><gtr:otherNames>Crispi F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0002-9378</gtr:issn><gtr:outcomeId>761F845EB49</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>421D3C18-80AF-486C-89CD-B692EB532587</gtr:id><gtr:title>Heparin elevates circulating soluble fms-like tyrosine kinase-1 immunoreactivity in pregnant women receiving anticoagulation therapy.</gtr:title><gtr:parentPublicationTitle>Circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dce14b357c7844c03c8a3040606b07d8"><gtr:id>dce14b357c7844c03c8a3040606b07d8</gtr:id><gtr:otherNames>Rosenberg VA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0009-7322</gtr:issn><gtr:outcomeId>pm_540e14ee14ec90c0d</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C8A77DDA-D6F0-4041-A8D4-7910EB47FE4C</gtr:id><gtr:title>Hepatitis C virus infection reduces hepatocellular polarity in a vascular endothelial growth factor-dependent manner.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d9e444d2922dd043f966085965c94caa"><gtr:id>d9e444d2922dd043f966085965c94caa</gtr:id><gtr:otherNames>Mee CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>437B171A003</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D7889162-BD98-4225-8592-4CC3A3EFF4AE</gtr:id><gtr:title>Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model.</gtr:title><gtr:parentPublicationTitle>Journal of cellular and molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba203c9c1182ed4c8f88fae7dbd07a8b"><gtr:id>ba203c9c1182ed4c8f88fae7dbd07a8b</gtr:id><gtr:otherNames>Bergmann A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1582-1838</gtr:issn><gtr:outcomeId>54F44732C96</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A6CB8D06-6312-48C1-A400-F11F54684556</gtr:id><gtr:title>The role of heterodimerization between VEGFR-1 and VEGFR-2 in the regulation of endothelial cell homeostasis.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3df86efa291578c18d072c2f5017785c"><gtr:id>3df86efa291578c18d072c2f5017785c</gtr:id><gtr:otherNames>Cudmore MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>pm_13962_22_22828632</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FC368C60-5CC1-4B54-94D5-553794503E44</gtr:id><gtr:title>Unravelling the theories of pre-eclampsia: are the protective pathways the new paradigm?</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b268a5b4f18e012b49c9c4df08170ee"><gtr:id>5b268a5b4f18e012b49c9c4df08170ee</gtr:id><gtr:otherNames>Ahmed A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>5442c4521465e0.62586365</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9AD55B51-9811-4CE9-BB5C-07A922CF2C6E</gtr:id><gtr:title>Angiopoietin-1 promotes atherosclerosis by increasing the proportion of circulating Gr1+ monocytes.</gtr:title><gtr:parentPublicationTitle>Cardiovascular research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d604ee1341cbc1b9b2547e5031d94928"><gtr:id>d604ee1341cbc1b9b2547e5031d94928</gtr:id><gtr:otherNames>Fujisawa T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0008-6363</gtr:issn><gtr:outcomeId>58991a458bb596.46742275</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F64712D-0F45-4C89-A738-70DD2C4D8F68</gtr:id><gtr:title>New insights into the etiology of preeclampsia: identification of key elusive factors for the vascular complications.</gtr:title><gtr:parentPublicationTitle>Thrombosis research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b268a5b4f18e012b49c9c4df08170ee"><gtr:id>5b268a5b4f18e012b49c9c4df08170ee</gtr:id><gtr:otherNames>Ahmed A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0049-3848</gtr:issn><gtr:outcomeId>UCy4ghMvbdb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>70F1A1CC-7E35-482A-8048-EE1B5EA15CE5</gtr:id><gtr:title>Autocrine activity of soluble Flt-1 controls endothelial cell function and angiogenesis.</gtr:title><gtr:parentPublicationTitle>Vascular cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/378c2178deeae7c8e4ad76a33c2416f8"><gtr:id>378c2178deeae7c8e4ad76a33c2416f8</gtr:id><gtr:otherNames>Ahmad S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>2045-824X</gtr:issn><gtr:outcomeId>5a3278ae7d39e9.96348775</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF581899-7590-4B14-8B5D-CD151017987A</gtr:id><gtr:title>Dysregulation of hydrogen sulfide producing enzyme cystathionine ?-lyase contributes to maternal hypertension and placental abnormalities in preeclampsia.</gtr:title><gtr:parentPublicationTitle>Circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5f5948b5a7f162e349b3184da5420ba0"><gtr:id>5f5948b5a7f162e349b3184da5420ba0</gtr:id><gtr:otherNames>Wang K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0009-7322</gtr:issn><gtr:outcomeId>pm_13962_22_23704251</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97EC6D13-EE46-47B3-A45A-41C33E5E4BD4</gtr:id><gtr:title>Antenatal corticosteroids impact the inflammatory rather than the antiangiogenic profile of women with preeclampsia.</gtr:title><gtr:parentPublicationTitle>Hypertension (Dallas, Tex. : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/540a43394e95f123344bacc64246ed15"><gtr:id>540a43394e95f123344bacc64246ed15</gtr:id><gtr:otherNames>Nayeri UA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0194-911X</gtr:issn><gtr:outcomeId>540746b2aba314.82356775</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD6681DB-C281-44FA-AC35-00CB12A70E31</gtr:id><gtr:title>The elevation in circulating anti-angiogenic factors is independent of markers of neutrophil activation in preeclampsia.</gtr:title><gtr:parentPublicationTitle>Angiogenesis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9463437bd7e5cb2602492c65f758bf0f"><gtr:id>9463437bd7e5cb2602492c65f758bf0f</gtr:id><gtr:otherNames>Ramma W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0969-6970</gtr:issn><gtr:outcomeId>pm_13962_22_22398973</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E10038AA-5872-4941-AE0E-735D366D74C1</gtr:id><gtr:title>Vascular endothelial growth factor signaling requires glycine to promote angiogenesis.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d76c43f0f634bd61dc061ab56aa2498"><gtr:id>5d76c43f0f634bd61dc061ab56aa2498</gtr:id><gtr:otherNames>Guo D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5a34f2a1399802.10392194</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2823EF02-E74F-4CBF-A026-2929BCFB1714</gtr:id><gtr:title>Loss of Akt activity increases circulating soluble endoglin release in preeclampsia: identification of inter-dependency between Akt-1 and heme oxygenase-1.</gtr:title><gtr:parentPublicationTitle>European heart journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3df86efa291578c18d072c2f5017785c"><gtr:id>3df86efa291578c18d072c2f5017785c</gtr:id><gtr:otherNames>Cudmore MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0195-668X</gtr:issn><gtr:outcomeId>pm_13962_22_21411816</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5CD1B394-6D43-4A4F-B3B1-6550A0DDB412</gtr:id><gtr:title>Carbon monoxide inhibits inward rectifier potassium channels in cardiomyocytes.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6719c5f874a49b478a9ed603868dc892"><gtr:id>6719c5f874a49b478a9ed603868dc892</gtr:id><gtr:otherNames>Liang S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>540746383aa7a2.85047886</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>842D2064-5F10-44AA-A550-4D74F18D4C8E</gtr:id><gtr:title>Angiotensin II induces soluble fms-Like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy.</gtr:title><gtr:parentPublicationTitle>Circulation research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25df2dcee136244bf1dc96c1beb9c9e5"><gtr:id>25df2dcee136244bf1dc96c1beb9c9e5</gtr:id><gtr:otherNames>Zhou CC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0009-7330</gtr:issn><gtr:outcomeId>p7b9NGXJdKG</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7C991F1C-E5A1-43D8-91F8-00808520EB7B</gtr:id><gtr:title>Multiple roles of angiopoietins in atherogenesis.</gtr:title><gtr:parentPublicationTitle>Current opinion in lipidology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b268a5b4f18e012b49c9c4df08170ee"><gtr:id>5b268a5b4f18e012b49c9c4df08170ee</gtr:id><gtr:otherNames>Ahmed A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0957-9672</gtr:issn><gtr:outcomeId>pm_13962_22_21881497</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>30B7C6C0-671C-4ADC-86A4-5AC511653E13</gtr:id><gtr:title>Upregulation of urotensin II receptor in preeclampsia causes in vitro placental release of soluble vascular endothelial growth factor receptor 1 in hypoxia.</gtr:title><gtr:parentPublicationTitle>Hypertension (Dallas, Tex. : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08f22f61c9c7ba04d5600e1d249f775a"><gtr:id>08f22f61c9c7ba04d5600e1d249f775a</gtr:id><gtr:otherNames>Gould PS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0194-911X</gtr:issn><gtr:outcomeId>pm_13962_22_20479331</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1443C5B8-A3FB-408C-AAA6-AB65E43A11E8</gtr:id><gtr:title>Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1.</gtr:title><gtr:parentPublicationTitle>Circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0215022fa505393f3ed57e409d1df60a"><gtr:id>0215022fa505393f3ed57e409d1df60a</gtr:id><gtr:otherNames>Cudmore M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0009-7322</gtr:issn><gtr:outcomeId>FDB35F11FD1</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0700288</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>FA7AA693-7EDD-4A7E-8CA3-6B5658FBF717</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Reproductive Health and Childbirth</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>